Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B. [PDF]
Wang S +12 more
europepmc +1 more source
B/F/TAF in people with both HIV-1 and hepatitis B: outcomes from the ALLIANCE open-label extension phase. [PDF]
Avihingsanon A +9 more
europepmc +1 more source
Molecular Basis and Clinical Significance of the High-risk Phenotype of Hepatitis B Virus Genotype C. [PDF]
Huang C, Liu Z, Zhang J, Shen T, Sang L.
europepmc +1 more source
Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis. [PDF]
Yang S +10 more
europepmc +1 more source
Management Of Patients With Hepatitis B Virus Reactivation Post-DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV-HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis. [PDF]
Osman HA +4 more
europepmc +1 more source
Baseline Liver Fibrosis Severity Predicts Superior HBeAg Clearance and Fibrosis Reversal following Peg-IFNα plus Nucleos(t)ide Analog Therapy in HBeAg-positive Chronic Hepatitis B Patients. [PDF]
Zhang Y +8 more
europepmc +1 more source
Core protein mutations are key determinants of hepatitis B virus replication during the hepatitis B e antigen-negative stage. [PDF]
Flichman D +4 more
europepmc +1 more source
Challenges in the Management of Hepatitis B Among Children and Adolescents: A 10-Year Single-Center Experience. [PDF]
Dobrzeniecka A +7 more
europepmc +1 more source
Traditional Chinese Medicine in Chronic Hepatitis B: Integrating Antiviral Effects and Immune Modulation in the Context of T Cell Exhaustion. [PDF]
Zhao X +6 more
europepmc +1 more source
RNA interference-mediated hepatitis B virus antigen shutdown enhances the antiviral immune effects of PEGylated interferon-α via T and B cell crosstalk remodeling. [PDF]
Zai W +10 more
europepmc +1 more source

